Adaptive Biotechnologies Quarterly Income Statement
NASDAQ: ADPTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Adaptive Biotechnologies revenue and earnings
In the quarter ended Jun 30, 2026, Adaptive Biotechnologies generated $71.6 million in revenue, up 21.5% from the same quarter a year earlier. Adaptive Biotechnologies reported a net loss of $39.8 million, compared with a loss of $25.6 million a year earlier. Gross margin was 71.8% (up from 69.4%) and operating margin -22.0%.
Diluted earnings per share came in at -$0.25.
Summary generated from market data by MetaCap's automated system. Methodology
Adaptive Biotechnologies income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 71.55M | 70.87M | 71.68M | 93.97M | 58.88M | 52.44M | 47.46M | 46.44M | 43.19M | 41.87M | 45.78M | 37.92M |
| Revenue growth (YoY) | +21.53% | +35.14% | +51.04% | +102.38% | +36.33% | +25.24% | +3.66% | +22.46% | -11.72% | +11.23% | -17.05% | -20.72% |
| Cost of Revenue | 20.16M | 18.71M | 18.22M | 18.16M | 18.00M | 16.98M | 18.05M | 16.67M | 19.32M | 18.05M | 19.62M | 19.35M |
| Gross Profit | 51.39M | 52.17M | 53.46M | 75.82M | 40.88M | 35.46M | 29.41M | 29.77M | 23.87M | 23.82M | 26.17M | 18.57M |
| Operating Expenses | 67.16M | 71.37M | 66.23M | 65.53M | 65.92M | 65.07M | 63.25M | 62.40M | 71.19M | 72.58M | 97.24M | 69.53M |
| Research & Development | 19.15M | 23.62M | 21.76M | 23.67M | 24.13M | 24.20M | 23.19M | 24.16M | 25.35M | 30.25M | 28.75M | 28.53M |
| Selling, General & Admin | 47.58M | 47.33M | 44.04M | 41.43M | 41.36M | 40.45M | 39.63M | 37.81M | 38.21M | 41.92M | 42.63M | 40.57M |
| Operating Income | -15.77M | -19.21M | -12.77M | 10.29M | -25.04M | -29.60M | -33.84M | -32.63M | -47.32M | -48.76M | -71.07M | -50.96M |
| Interest Expense | 2.69M | 2.89M | 2.95M | 2.97M | 2.95M | 2.90M | 2.95M | 2.94M | 2.70M | 2.99M | 3.01M | 3.65M |
| Net Income | -39.79M | -20.03M | -13.58M | 9.55M | -25.61M | -29.85M | -33.69M | -32.07M | -46.22M | -47.51M | -69.44M | -50.30M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.25 | -0.13 | -0.08 | 0.06 | -0.17 | -0.20 | -0.22 | -0.22 | -0.31 | -0.33 | -0.48 | -0.35 |
| EPS (Diluted) | -0.25 | -0.13 | -0.08 | 0.06 | -0.17 | -0.20 | -0.22 | -0.22 | -0.31 | -0.33 | -0.48 | -0.35 |
| Shares Outstanding (Basic) | 159.86M | 155.52M | — | 152.43M | 152.08M | 149.20M | — | 147.52M | 147.41M | 145.79M | — | 144.70M |
| Shares Outstanding (Diluted) | 159.86M | 155.52M | — | 163.16M | 152.08M | 149.20M | — | 147.52M | 147.41M | 145.79M | — | 144.70M |
| EBITDA | -12.50M | -15.82M | -9.12M | 14.26M | -20.96M | -25.32M | -29.91M | -28.48M | -42.75M | -43.55M | -68.31M | -45.19M |
| Gross Margin | 71.82% | 73.60% | 74.58% | 80.68% | 69.43% | 67.62% | 61.98% | 64.11% | 55.27% | 56.89% | 57.16% | 48.98% |
| Operating Margin | -22.04% | -27.10% | -17.82% | 10.95% | -42.52% | -56.45% | -71.30% | -70.27% | -109.56% | -116.45% | -155.22% | -134.38% |
| Net Margin | -55.61% | -28.27% | -18.94% | 10.16% | -43.50% | -56.92% | -70.99% | -69.07% | -107.02% | -113.45% | -151.67% | -132.65% |
This table shows 12 quarterly periods of Adaptive Biotechnologies's income statement, from Q2 2026 back to Q3 2023, across 18 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow ADPT's reporting calendar. What is a income statement?